作者
Xavier Ligneau, D Perrin, L Landais, J-C Camelin, TPG Calmels, I Berrebi-Bertrand, J-M Lecomte, R Parmentier, C Anaclet, J-S Lin, V Bertaina-Anglade, C Drieu la Rochelle, F d'Aniello, A Rouleau, F Gbahou, J-M Arrang, CR Ganellin, H Stark, W Schunack, J-C Schwartz
发表日期
2007/1/1
期刊
Journal of Pharmacology and Experimental Therapeutics
卷号
320
期号
1
页码范围
365-375
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Histamine H3 receptor inverse agonists are known to enhance the activity of histaminergic neurons in brain and thereby promote vigilance and cognition. 1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor. On the stimulation of guanosine 5′-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity ∼50% higher than that of ciproxifan. Its in vitro potency was ∼6 times lower at the rodent receptor. In mice, the oral bioavailability coefficient, i.e., the ratio of plasma areas under the curve after oral and i.v. administrations, respectively, was 84%. BF2.649 dose dependently enhanced tele-methylhistamine levels in mouse brain, an index of …
引用总数
2007200820092010201120122013201420152016201720182019202020212022202320246202018241613981915121214141393